JPM vs MPA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MPA exhibits a stable Piotroski F-Score of 6/9, but this is overshadowed by severe valuation and dividend sustainability issues. The stock is trading at $11.24, significantly above its Graham Number ($9.59) and Intrinsic Value ($9.74), indicating it is overvalued. Most critically, a payout ratio of 223.36% suggests the dividend is unsustainable and likely funded by capital erosion or leverage. Combined with a bearish technical trend (0/100) and a very low current ratio (0.14), the risk profile is high.
Compare Another Pair
Related Comparisons
JPM vs MPA: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and BlackRock MuniYield Pennsylvania Quality Fund (MPA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.